Insider · CIK 0001763923

Gupta Suneel

Reports to the SEC for 1 company · NEWARK, CA

sec.gov

Transactions

Companies

Filings

CIK

0001763923

Forms 4 and 5

Insider transactions

36 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2024-11-26	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+30K sh	$12.17	+$365K	286,174
2024-11-26	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−450 sh	—	—	93,300
2024-11-26	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−30K sh	—	—	93,750
2024-11-26	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+450 sh	$12.17	+$5,476.5	267,433
2024-11-26	PTGXProtagonist Therapeutics, IncS Sale	Chief Development Officer	SSale	−19.2K sh	$45.50	−$873K	266,983
2024-11-25	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−45K sh	—	—	0
2024-11-25	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+85K sh	$7.80	+$663K	359,611
2024-11-25	PTGXProtagonist Therapeutics, IncS Sale	Chief Development Officer	SSale	−103K sh	$46.04	−$4.76M	256,174
2024-11-25	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+45K sh	$7.38	+$332K	229,611
2024-11-25	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+45K sh	$8.02	+$361K	274,611
2024-11-25	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−85K sh	—	—	0
2024-11-25	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−45K sh	—	—	0
2024-02-26	PTGXProtagonist Therapeutics, IncF Tax Payment	Chief Development Officer	FTax Payment	−4,282 sh	$29.53	−$126K	183,285
2024-01-09	PTGXProtagonist Therapeutics, IncS Sale	Chief Development Officer	SSale	−5,000 sh	$25.00	−$125K	187,567
2024-01-09	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+5,000 sh	$7.38	+$36.9K	192,567
2024-01-09	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−5,000 sh	—	—	45,000
2024-01-02	PTGXProtagonist Therapeutics, IncA Award	Chief Development Officer	AAward	+19.3K sh	—	—	187,567
2024-01-02	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)A Award	Chief Development Officer	AAward	+71.5K sh	—	—	71,500
2023-10-19	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+20K sh	$7.38	+$148K	168,317
2023-10-19	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−20K sh	—	—	50,000
2023-05-31	PTGXProtagonist Therapeutics, IncF Tax Payment	Chief Development Officer	FTax Payment	−4,150 sh	$26.07	−$108K	148,037
2023-05-31	PTGXProtagonist Therapeutics, IncA Award	Chief Development Officer	AAward	+12K sh	—	—	152,187
2023-01-16	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)A Award	Chief Development Officer	AAward	+124K sh	—	—	123,750
2023-01-16	PTGXProtagonist Therapeutics, IncA Award	Chief Development Officer	AAward	+20.6K sh	—	—	138,187
2022-04-26	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−40K sh	—	—	70,000
2022-04-26	PTGXProtagonist Therapeutics, IncM Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+40K sh	$7.38	+$295K	117,561
2022-02-28	PTGXProtagonist Therapeutics, IncF Tax Payment	Chief Development Officer	FTax Payment	−649 sh	$24.28	−$15.8K	77,007
2022-02-15	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)A Award	Chief Development Officer	AAward	+75K sh	—	—	75,000
2022-02-15	PTGXProtagonist Therapeutics, IncA Award	Chief Development Officer	AAward	+12.5K sh	—	—	77,656
2021-02-26	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)A Award	Chief Development Officer	AAward	+80K sh	—	—	80,000
2021-02-26	PTGXProtagonist Therapeutics, IncA Award	Chief Development Officer	AAward	+12K sh	—	—	63,987
2020-02-28	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)A Award	Chief Development Officer	AAward	+85K sh	—	—	85,000
2019-12-03	PTGXProtagonist Therapeutics, IncP Purchase	Chief Development Officer	PPurchase	+30K sh	$5.13	+$154K	49,500
2019-02-28	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)A Award	Chief Development Officer	AAward	+45K sh	—	—	45,000
2019-02-28	PTGXProtagonist Therapeutics, IncA Award	Chief Development Officer	AAward	+7,500 sh	—	—	17,500
2019-01-15	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+110K sh	—	—	110,000

Recent filings

Accepted (ET)
Nov 274
Gupta Suneel0001104659-24-123807
SEC(opens sec.gov)
Feb 284
Gupta Suneel0001104659-24-028886
SEC(opens sec.gov)
Jan 114
Gupta Suneel0001104659-24-003435
SEC(opens sec.gov)
Jan 44
Gupta Suneel0001104659-24-001495
SEC(opens sec.gov)
Oct 234
Gupta Suneel0001104659-23-110803
SEC(opens sec.gov)

Companies

Protagonist Therapeutics, IncChief Development OfficerPTGX

Address

7707 GATEWAY BLVD., SUITE 140

NEWARK, CA, 94560